SOURCE: Addison-Davis Diagnostics, Inc.

September 02, 2005 12:37 ET

Survey Finds Drug Awareness in Middle Schools Is Sharply on the Rise

WESTLAKE VILLAGE, CA -- (MARKET WIRE) -- September 2, 2005 -- Addison-Davis Diagnostics, Inc. (OTC BB: ADDI) has become aware of a recent survey conducted by Columbia University. Twenty-eight percent of middle-school-student respondents reported that drugs are used, kept or sold at their schools, a 47 percent jump since 2002, according to the 10th annual teen survey by Columbia's National Center on Addiction and Substance Abuse.

"These statistics are a striking insight into the increasing number of children affected by drugs in this country. We are prepared to assist parents throughout the country and be viewed as a partner in their fight against drugs in their children's lives," stated Edward W. Withrow III, CEO of Addison-Davis Diagnostics, Inc.

According to the survey, twelve- to seventeen-year-olds who report that there are drugs in their schools are three times likelier to try marijuana and twice as likely to drink alcohol than teens who say their schools are drug free. "Availability is the mother of use," said Joseph Califano Jr., the center's president. "We really are putting an enormous number of 12- to 17-year-olds at great risk."

Most of the teens surveyed -- 58 percent -- said the legality of cigarettes has no effect on their decision to smoke or abstain, and 48 percent said the fact that marijuana is illegal doesn't affect whether they use or don't use the drug. The report found that teens who confided in their parents were at much lower risk of drug abuse.

The "Parents' Tool" Drug Test, an FDA 510K approved self-contained NIDA (National Institute of Drug Abuse) 5-panel drug test, will be marketed by national retail chains throughout the United States. The "Parents' Tool" drug test will screen for Amphetamines (Crystal Meth), Cocaine, Opiates, Phencyclidine (PCP) and Marijuana (THC).

About Addison-Davis

Addison-Davis Diagnostics, Inc. is responding to industry demands by supplying quick response diagnostic tests that are user friendly, produce fast, simple results and are less costly, less problematic and less time consuming. Addison-Davis is currently focused on bringing fast and reliable "Point-of-care" Diagnostic Testing through the use of its patented technology to Healthcare Professionals, Hospitals, certain branches of the Government and the Workplace environment for drugs-of-abuse and medical conditions and diseases. For more information please visit our website or contact Matt Maguire 1-866 THE APPL(E).

Safe Harbor

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

Contact Information

  • Contact:
    Melissa Owens